In 2020, the DIAVIR project, which is based ona transcriptomic signature that distinguishes bacterial from viral infection,joined the Bioincubatech Program for further advancing this GENVIP group’sresearch area.BioIncubaTech is a High-Tech Incubator for thepromotion of innovation and transfer of biotechnology in the field of healthand food technologies to micro-SMEs.
This initiative is promoted by theUniversity of Santiago de Compostela (Spain) and funded by the INCYDEFoundation, within the framework of the ERDF Operational Program for SmartGrowth 2014ES16RFOP001, through the Spanish Chamber of Commerce as anintermediate body.
In 2021, the DIAVIR research project entered the USC Transfer Acceleration program: "USC Accelerator" for further advancing research in the field of transcriptomic markers, DIAVIR.
Specifically, the USC Accelerator allowed progress in the evaluation of different amplification methods to assess their suitability for rapid detection of RNA biomarkers.
The Vaccine Research Unit of the HealthResearch Institute of Santiago de Compostela [Instituto de Investigación Sanitaria de Santiago (IDIS)], supported and sponsored by Sanofi Pasteur MSD, developed an interactive cloud-based platform for real-time interaction with an international panel of experts on a particular topic through any device (computer, mobile app).
The topic of the first edition was “Rotavirus and Rotavirus-Vaccines”, and it was carried out with the active contribution of Prof. Adam Finn (University of Bristol, United Kingdom), Prof. Carlo Giaquinto (University of Padova, Italy) and Prof. Timo Vesikari (University of Tampere, Finland), all of whom are leading experts in the field of infectious diseases and vaccinology, particularly, rotavirus.
The expert's panel identified three thematic areas for discussion:
Patent Registration Nº 02/2012/714
Filed on 16 May 2012 at the Intellectual Property Registry of Galicia